MedPath

Anticoagulation Therapy After Splenectomy in Cirrhosis Patient

Phase 1
Completed
Conditions
Portal Hypertension
Thrombosis
Liver Cirrhosis
Anticoagulant-induced Bleeding
Interventions
Registration Number
NCT04397289
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Brief Summary

1. Inclusion and Exclusion Criteria Inclusion criteria: Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and portal hypertension.

Exclusion criteria:

1. ) Portal vein system thrombosis (PVST) found by preoperative color Doppler ultrasound or MRI examination;

2. ) Liver cirrhosis complicated with liver tumor;

3. ) Liver cirrhosis complicated with blood system diseases;

4. ) Patients who have not signed the informed consent form.

2. Research subgroup According to the order of the patients, the following groups are entered in turn, and the cycle is repeated.

1. ) Heparin group

2. ) Rivaroxaban group

3. ) Control group.

Detailed Description

1. Inclusion and Exclusion Criteria Inclusion criteria: Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and portal hypertension.

Exclusion criteria:

1. ) Portal vein system thrombosis (PVST) found by preoperative color Doppler ultrasound or MRI examination;

2. ) Liver cirrhosis complicated with liver tumor;

3. ) Liver cirrhosis complicated with blood system diseases;

4. ) Patients who have not signed the informed consent form.

2. Research subgroup According to the order of the patients, the following groups are entered in turn, and the cycle is repeated.

1. ) Heparin group: Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation. Warfarin 1.25-2.5 mg po qd, 30 days after operation. PT(prothrombin time)/INR(international normalized ratio) was kept at 1.25-1.5.

2. ) Rivaroxaban group: Rivaroxaban 10mg po qd from 24 hours after operation, 30 days after operation. PT/INR was kept at 1.25-1.5.

3. ) Control group: No preventive intervention measures. If platelets in the above groups are \> 500× 109/L, aspirin 100 mg qd is added for 1 month. If platelets are \> 1000× 109/L, platelet collection is performed.

3. Monitoring indicators Color Doppler ultrasound was reexamined 1, 2, 3 and 4 weeks after operation to find out whether PVST was present. Abdominal CT was performed when PVST was suspected. After the patient's condition is stable, the portal vein system ultrasound is reviewed monthly, and the follow-up time is 1 year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and portal hypertension
Exclusion Criteria
  • Portal vein thrombosis found by preoperative color Doppler ultrasound or MRI examination;
  • Liver cirrhosis complicated with liver tumor;
  • Liver cirrhosis complicated with blood system diseases;
  • Patients who have not signed the informed consent form.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Rivaroxaban groupHeparin and RivaroxabanRivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation. PT/INR was kept at 1.25-1.5.
Heparin groupHeparin and RivaroxabanLow molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation. Warfarin 1.25-2.5 mg po qd, 30 days after operation. PT/INR was kept at 1.25-1.5.
Control groupHeparin and RivaroxabanNo preventive intervention measures.
Primary Outcome Measures
NameTimeMethod
thrombosis formation1 year after surgery.

The evaluation index is the incidence of PVST

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

the first hospital of xi'an jiaotong University

🇨🇳

Xi'an, Shaanxi, China

© Copyright 2025. All Rights Reserved by MedPath